Aardvark Therapeutics Faces Major Investor Concerns After Drug Trial Halt
Aardvark Therapeutics Faces Investor Scrutiny Amid Troubling Developments
On March 2, 2026, investors were rocked by a drastic decline in Aardvark Therapeutics’ stock, which fell by 56%, leaving shares at $7.02 after the company announced the suspension of its Phase 3 Hunger Elimination of Reduction Objective (HERO) trial. This trial was aimed at assessing ARD-101 as a potential treatment for hyperphagia, a condition associated with Prader-Willi Syndrome (PWS). The sudden halt stemmed from serious safety concerns characterized by
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.